Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | Director | June 05, 2025 | June 09, 2025 |
| HTG MOLECULAR DIAGNOSTICS, INCHTGM · Entity 112530 | Director | September 15, 2022 | September 15, 2022 |
| MDxHealth SAMDXH · Entity 7018 | Director | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date June 05, 2025 · Filed June 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,706 |
Reported balance
After 2025-06-05 transaction · row 1
1 source rowRow 1 · 2025-06-05 · Exercise / conversion · Acquired 15,706 · Balance 15,706 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-05 · Exercise / conversion · Disposed 15,706 · Balance 0 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2: 100% of the shares subject to the RSU Award vested on June 5, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: 100% of the shares subject to the RSU Award vested on June 5, 2025.
HTG MOLECULAR DIAGNOSTICS, INC
Report date September 15, 2022 · Filed September 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.86 · Expires 2032-09-14 | Direct | 4,000 |
Reported balance
After 2022-09-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-15 · Grant · Acquired 4,000 · Balance 4,000 F1: The shares will vest on the earlier of September 15, 2023 or the date of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares will vest on the earlier of September 15, 2023 or the date of the next annual meeting of stockholders.
MDxHealth SA
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.76 · Expires 2036-05-28 | Direct | 10,000 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 10,000 · Balance 10,000 F1: Represents options to purchase 10,000 ordinary shares of the Issuer at a price per share of $0.76 granted on June 1, 2026 which vest in full on the date of the annual general shareholders' meeting that takes place in the calendar year following the calendar year in which the options were granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase 10,000 ordinary shares of the Issuer at a price per share of $0.76 granted on June 1, 2026 which vest in full on the date of the annual general shareholders' meeting that takes place in the calendar year following the calendar year in which the options were granted.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 21:30 UTC | MDxHealth SA MDXH · Entity 7018 | GrantShare Option · Derivative | 10,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001193125-26-255815 · ownership.xml · derivative · entry 1 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2036-05-28 F1 · derivative.exercise_date: Represents options to purchase 10,000 ordinary shares of the Issuer at a price per share of $0.76 granted on June 1, 2026 which vest in full on the date of the annual general shareholders' meeting that takes place in the calendar year following the calendar year in which the options were granted. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:08 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 15,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-016316 · form4-06092025_090627.xml · derivative · entry 2 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,706 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 100% of the shares subject to the RSU Award vested on June 5, 2025. F2 · derivative.expiration_date: 100% of the shares subject to the RSU Award vested on June 5, 2025. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:08 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 15,706 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-016316 · form4-06092025_090627.xml · nonDerivative · entry 1 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:51 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (right to buy) · Derivative | 23,076 | $0.00 Strike: $5.73 | $0.00 |
DisclosureSEC source: 0001415889-24-016076 · form4-06072024_100635.xml · derivative · entry 2 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,076 Underlying: Common Stock · 23,076 shares Expires 2034-06-05 Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:51 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 15,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016076 · form4-06072024_100635.xml · derivative · entry 1 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,706 Underlying: Common Stock · 15,706 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 100% of the shares subject to the RSU Award shall vest on June 5, 2025. F2 · derivative.expiration_date: 100% of the shares subject to the RSU Award shall vest on June 5, 2025. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 22:38 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (right to buy) · Derivative | 30,242 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001209191-23-038080 · doc4.xml · derivative · entry 1 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,242 Underlying: Common Stock · 30,242 shares Expires 2033-06-14 Read SEC document |
| September 15, 2022 Filed Sep 15, 2022 18:08 UTC | HTG MOLECULAR DIAGNOSTICS, INC HTGM · Entity 112530 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001209191-22-050146 · doc4.xml · derivative · entry 1 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2032-09-14 F1 · derivative.exercise_date: The shares will vest on the earlier of September 15, 2023 or the date of the next annual meeting of stockholders. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 21:32 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (right to buy) · Derivative | 47,013 | $0.00 Strike: $9.67 | $0.00 |
DisclosureSEC source: 0001209191-22-034253 · doc4.xml · derivative · entry 1 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,013 Underlying: Common Stock · 47,013 shares Expires 2032-06-01 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest monthly over three years from the vesting commencement date of June 1, 2022. The option becomes fully vested on June 1, 2025. Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 17:15 UTC | HTG MOLECULAR DIAGNOSTICS, INC HTGM · Entity 112530 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001209191-21-052581 · doc4.xml · derivative · entry 1 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2031-08-17 F1 · derivative.exercise_date: The shares will vest on the earlier of August 18, 2022 or the date of the next annual meeting of stockholders. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 16:59 UTC | HTG MOLECULAR DIAGNOSTICS, INC HTGM · Entity 112530 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001209191-20-047959 · doc4.xml · derivative · entry 1 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-08-18 F1 · derivative.exercise_date: The shares will vest on the earlier of August 19, 2021 or the date of the next annual meeting of stockholders. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 16:30 UTC | HTG MOLECULAR DIAGNOSTICS, INC HTGM · Entity 112530 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-19-046327 · doc4.xml · derivative · entry 2 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-08-13 F1 · derivative.exercise_date: The shares will vest on the earlier of August 14, 2020 or the date of the next annual meeting of stockholders. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 16:30 UTC | HTG MOLECULAR DIAGNOSTICS, INC HTGM · Entity 112530 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-046327 · doc4.xml · nonDerivative · entry 1 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 17:27 UTC | HTG MOLECULAR DIAGNOSTICS, INC HTGM · Entity 112530 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0001209191-18-047485 · doc4.xml · derivative · entry 2 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-08-14 F1 · derivative.exercise_date: The shares will vest on the earlier of August 15, 2019 or the date of the next annual meeting of stockholders. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 17:27 UTC | HTG MOLECULAR DIAGNOSTICS, INC HTGM · Entity 112530 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-047485 · doc4.xml · nonDerivative · entry 1 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 17:07 UTC | HTG MOLECULAR DIAGNOSTICS, INC HTGM · Entity 112530 | GrantCommon Stock | 7,500 | $2.05 | $15,375.00 |
DisclosureSEC source: 0001209191-17-050160 · doc4.xml · nonDerivative · entry 1 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · shares: The shares were acquired by the Reporting Person pursuant to the Issuer's Amended and Restated Stock Purchase Plan adopted December 1, 2015, as amended January 21, 2016. Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 16:29 UTC | HTG MOLECULAR DIAGNOSTICS, INC HTGM · Entity 112530 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001209191-17-049211 · doc4.xml · derivative · entry 1 HARDISON DON M · CIK 0001209588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-08-14 F1 · derivative.exercise_date: The shares will vest monthly in equal installments over a one-year period such that the stock option is fully vested on August 15, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.